Security
Verrica Pharmaceuticals Inc. Common Stock · VRCA
VRCANASDAQCommon stockCurrentCIK 1660334Updated Oct 6, 2026
VRCA price & chart
Loading TradingView…
NASDAQ:VRCA on TradingView ↗About the company
Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
In the news
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference ↗
Recent filings
4 filing
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 40,896,000Source | 32,927,000Source | 36,017,000Source | 39,107,000Source | 52,010,000Source | 38,786,000Source | 42,178,000Source | 66,307,000Source | 47,131,000Source | 54,134,000Source | 81,597,000Source | 44,721,000Source |
| Property, Plant and Equipment, NetUSD | 225,000Source | 651,000Source | 177,000Source | 315,000Source | 710,000Source | 191,000Source | 537,000Source | 937,000Source | 209,000Source | 589,000Source | 1,052,000Source | 3,887,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,097,000Source | 22,959,000Source | 11,198,000Source | 15,396,000Source | 31,930,000Source | 20,600,000Source | 29,595,000Source | 48,939,000Source | 30,147,000Source | 46,329,000Source | 69,547,000Source | 34,273,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 7,047,000Source | 0Source | 10,939,000Source | 9,193,000Source | 10,026,000Source | 7,724,000Source | 5,607,000Source | 7,002,000Source | 5,260,000Source | 48,000Source | 4,248,000Source | — |
| Inventory, NetUSD | 2,304,000Source | 2,584,000Source | 2,712,000Source | 2,522,000Source | 2,704,000Source | 1,974,000Source | 2,459,000Source | 2,499,000Source | 2,236,000Source | 2,463,000Source | 1,022,000Source | — |
| Assets, CurrentUSD | 36,275,000Source | 28,187,000Source | 32,639,000Source | 36,781,000Source | 47,318,000Source | 34,129,000Source | 39,474,000Source | 61,376,000Source | 42,539,000Source | 51,179,000Source | 77,530,000Source | 39,115,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,586,000Source | 2,560,000Source | 2,619,000Source | 1,492,000Source | 2,476,000Source | 2,368,000Source | 1,767,000Source | 2,344,000Source | 2,801,000Source | 2,310,000Source | 2,545,000Source | 4,355,000Source |
| Operating Lease, Right-of-Use AssetUSD | 616,000Source | 912,000Source | 384,000Source | 690,000Source | 1,005,000Source | 463,000Source | 764,000Source | 1,082,000Source | 540,000Source | 836,000Source | 1,158,000Source | 1,443,000Source |
| Other Assets, NoncurrentUSD | 376,000Source | 538,000Source | 638,000Source | 376,000Source | 453,000Source | 640,000Source | 376,000Source | 452,000Source | 376,000Source | 376,000Source | 452,000Source | 276,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 57,936,000Source | 66,978,000Source | 31,710,000Source | 56,591,000Source | 65,310,000Source | 22,731,000Source | 60,754,000Source | 64,799,000Source | 22,388,000Source | 63,994,000Source | 61,834,000Source | 4,688,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,000Source | 5,000Source | 2,000Source | 1,000Source | 4,000Source | 2,000Source | 9,000Source | 4,000Source | 2,000Source | 9,000Source | 4,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -316,839,000Source | -290,825,000Source | -347,748,000Source | -316,565,000Source | -267,965,000Source | -334,595,000Source | -316,769,000Source | -250,779,000Source | -324,913,000Source | -307,027,000Source | -230,448,000Source | -163,453,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Stockholders' Equity Attributable to ParentUSD | -17,040,000Source | -34,051,000Source | 4,307,000Source | -17,484,000Source | -13,300,000Source | 16,055,000Source | -18,576,000Source | 1,508,000Source | 24,743,000Source | -9,860,000Source | 19,763,000Source | 40,033,000Source |
| Additional Paid in Capital, Common StockUSD | 299,798,000Source | 256,769,000Source | 352,053,000Source | 299,080,000Source | 254,661,000Source | 350,648,000Source | 298,184,000Source | 252,287,000Source | 349,654,000Source | 297,158,000Source | 250,207,000Source | 203,482,000Source |
| Liabilities and EquityUSD | 40,896,000Source | 32,927,000Source | 36,017,000Source | 39,107,000Source | 52,010,000Source | 38,786,000Source | 42,178,000Source | 66,307,000Source | 47,131,000Source | 54,134,000Source | 81,597,000Source | 44,721,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 28,908,000Source | 21,026,000Source | 22,442,000Source | 29,222,000Source | 20,051,000Source | 16,219,000Source | 29,396,000Source | 19,365,000Source | 16,437,000Source | 29,012,000Source | 17,024,000Source | 3,459,000Source |
| Operating Lease, Liability, CurrentUSD | 335,000Source | 315,000Source | 355,000Source | 328,000Source | 332,000Source | 348,000Source | 321,000Source | 331,000Source | 341,000Source | 315,000Source | 324,000Source | 297,000Source |
| Accounts Payable, CurrentUSD | 1,585,000Source | 966,000Source | 1,603,000Source | 2,321,000Source | 1,150,000Source | 2,193,000Source | 1,443,000Source | 2,527,000Source | 2,072,000Source | 1,896,000Source | 2,464,000Source | 507,000Source |
| Operating Lease, Liability, NoncurrentUSD | 330,000Source | 665,000Source | 61,000Source | 416,000Source | 744,000Source | 152,000Source | 500,000Source | 825,000Source | 242,000Source | 583,000Source | 910,000Source | 1,229,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | 10,000,000Source | — | — | 10,000,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Long-term DebtUSD | 21,619,000Source | 43,305,000Source | — | 24,578,000Source | 42,751,000Source | — | 27,809,000Source | 42,848,000Source | 0Source | 30,983,000Source | 42,874,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 12,458,000Source | — | — | 12,673,000Source | — | — | 12,821,000Source | — | 0Source | 12,938,000Source | — | — |
| Deferred Revenue, Current | — | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | -9,742,000Source | — | -76,579,000Source | -66,995,000Source | -24,487,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 2,464,000Source | 5,559,000Source | 5,212,000Source | -4,200,000Source | 3,860,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 121,000Source | -453,000Source | 176,000Source | -568,000Source | 2,201,000Source | -338,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -9,163,000Source | -12,677,000Source | -17,627,000Source | -60,927,000Source | -38,577,000Source | -18,650,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | -19,000Source | -362,000Source | 54,041,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | 27,000Source | 362,000Source | 302,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -120,000Source | -4,057,000Source | 1,445,000Source | 37,728,000Source | 74,213,000Source | -16,870,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -9,283,000Source | -16,734,000Source | -16,182,000Source | -23,218,000Source | 35,274,000Source | 18,521,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 21,097,000Source | 22,959,000Source | 11,460,000Source | 15,396,000Source | 20,864,000Source | 29,595,000Source | 30,147,000Source | 46,329,000Source | 69,547,000Source | 34,273,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 20,000Source | 1,535,000Source | 5,171,000Source | 7,226,000Source | 3,152,000Source | 1,789,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 718,000Source | 2,108,000Source | 1,213,000Source | 888,000Source | 897,000Source | 1,026,000Source | 3,318,000Source | 7,164,000Source | 14,376,000Source | 4,985,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | 10,000,000Source | — | 10,000,000Source | — | — |
| DepreciationUSD | — | — | 21,807Source | 100,000Source | — | — | 17,000Source | 52,000Source | 133,000Source | 342,000Source | 530,000Source | 454,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 34,000Source | 0Source | 0Source | 598,000Source | 0Source | 254,000Source | 2,648,000Source | -2,648,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | -246,000Source | -83,000Source | -2,537,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | -246,000Source | -83,000Source | -2,537,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | -10,000Source | -3,000Source | -1,000Source | -19,000Source | 0Source | -6,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -1,533,000Source | — | 0Source | -1,437,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 17,405,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| InterestExpenseNonoperatingUSD | — | — | 2,094,000Source | 2,376,000Source | 164,000Source | 2,131,000Source | 160,000Source | 2,203,000Source | 7,742,000Source | 9,412,000Source | — | — |
| Investment Income, InterestUSD | — | — | 159,000Source | 221,000Source | 111,000Source | 228,000Source | 201,000Source | 337,000Source | 929,000Source | 1,417,000Source | 2,740,000Source | 476,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 29,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -274,000Source | -22,860,000Source | -13,153,000Source | 204,000Source | -9,682,000Source | -9,742,000Source | -17,886,000Source | -76,579,000Source | -66,995,000Source | -24,487,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,901,000Source | -2,156,000Source | -56,000Source | -1,306,000Source | 33,000Source | -1,612,000Source | -5,701,000Source | -10,660,000Source | -1,236,000Source | -3,191,000Source |
| Operating ExpensesUSD | — | — | 12,717,000Source | 18,923,000Source | 18,959,000Source | 11,192,000Source | 14,738,000Source | 11,569,000Source | 47,762,000Source | 73,485,000Source | 70,883,000Source | 30,328,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 98,000Source | — | — | — | — | — | — | 282,000Source | 376,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | -1,000Source | -3,000Source | -1,000Source | -8,000Source | 0Source | -3,000Source | -17,000Source | -14,000Source | -58,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 26,901,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 0Source | 155,000Source | 7,000Source | 0Source |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 14,344,000Source | -1,781,000Source | 5,862,000Source | 12,702,000Source | 5,023,000Source | 3,439,000Source | 35,577,000Source | 7,566,000Source | 5,124,000Source | 9,032,000Source |
| Cost of Goods and Services Sold | — | — | — | —Source | — | — | — | —Source | — | —Source | —Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 9,403,000Source | 16,083,000Source | 10,349,000Source | 8,852,000Source | 9,989,000Source | 8,848,000Source | 35,220,000Source | 58,822,000Source | 47,305,000Source | — |
| Operating Income (Loss)USD | — | — | 1,627,000Source | -20,704,000Source | -13,097,000Source | 1,510,000Source | -9,715,000Source | -8,130,000Source | -12,185,000Source | -65,919,000Source | -65,759,000Source | -21,296,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | -1,000Source | -3,000Source | -1,000Source | -8,000Source | 0Source | -3,000Source | -17,000Source | -14,000Source | -58,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -274,000Source | -22,860,000Source | -13,153,000Source | 204,000Source | -9,682,000Source | -9,742,000Source | -17,886,000Source | -76,579,000Source | -66,995,000Source | -24,487,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.03Source | -4.88Source | -0.62Source | 0.02Source | -0.45Source | -1.03Source | -1.68Source | -1.48Source | -1.48Source | -0.72Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.03Source | -4.88Source | -0.62Source | 0.02Source | -0.45Source | -1.03Source | -1.68Source | -1.48Source | -1.48Source | -0.72Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 9,490,083Source | 4,680,543Source | 21,305,025Source | 9,488,055Source | 21,305,025Source | 9,483,734Source | 10,652,367Source | 51,808,228Source | 45,342,451Source | 34,163,437Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 9,490,083Source | 4,680,543Source | 21,305,025Source | 9,490,600Source | 21,305,025Source | 9,483,734Source | 10,652,367Source | 51,808,228Source | 45,342,451Source | 34,163,437Source |
| Interest Expense (non-operating)USD | — | — | 2,094,000Source | 2,376,000Source | 164,000Source | 2,131,000Source | 160,000Source | 2,203,000Source | 7,742,000Source | 9,412,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 17,405,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 3,962,000Source | 2,172,000Source |
| Investment Income, InterestUSD | — | — | 159,000Source | 221,000Source | 111,000Source | 228,000Source | 201,000Source | 337,000Source | 929,000Source | 1,417,000Source | 2,740,000Source | 476,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,901,000Source | -2,156,000Source | -56,000Source | -1,306,000Source | 33,000Source | -1,612,000Source | -5,701,000Source | -10,660,000Source | -1,236,000Source | -3,191,000Source |
| Operating ExpensesUSD | — | — | 12,717,000Source | 18,923,000Source | 18,959,000Source | 11,192,000Source | 14,738,000Source | 11,569,000Source | 47,762,000Source | 73,485,000Source | 70,883,000Source | 30,328,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 98,000Source | — | — | — | — | — | — | 282,000Source | 376,000Source |
| Research and Development ExpenseUSD | — | — | 2,205,000Source | 2,405,000Source | 6,034,000Source | 1,846,000Source | 3,860,000Source | 2,284,000Source | 8,855,000Source | 11,840,000Source | 20,295,000Source | 12,198,000Source |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
d13828dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d13828dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results - Company reports record demand for YCANTH ® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year - - Topline data from global Phase 3 program studying common warts currently expected in mid-2027 - - The Company’s cash runway could extend into 2028 based on its current operating plan and assuming f…
Read attachment ↗d152529dex991.htm · 8-K · 2026-05-12
EX-99.1 2 d152529dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results - Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch - - Company announces achievement of over 50% of current targeted enrollment in the first trial in global Phase 3 common warts program …
Read attachment ↗d94203dex991.htm · 8-K · 2026-03-11
EX-99.1 2 d94203dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - YCANTH ® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 - - Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year - - YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 - Comp…
Read attachment ↗d692687dex41.htm · 8-K · 2025-11-24
EX-4.1 2 d692687dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (…
Read attachment ↗d692687dex42.htm · 8-K · 2025-11-24
EX-4.2 3 d692687dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (…
Read attachment ↗d692687dex991.htm · 8-K · 2025-11-24
EX-99.1 7 d692687dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica’s Board of Dir…
Read attachment ↗